Significance of increasing levels of minimal residual disease in patients with philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response

Journal of Clinical Oncology

Volumn 27, Issue 22, 2009, Pages 3659-3663

  Kantarjian, Hagop M ^a   Shan, Jianqin ^a   Jones, Daniel ^a   O'Brien, Susan ^a   Rios, Mary Beth ^a   Jabbour, Elias ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BOSUTINIB; DASATINIB; IMATINIB; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADULT; ARTICLE; CANCER GROWTH; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; CAUSE OF DEATH; COHORT ANALYSIS; COMPARATIVE STUDY; CYTOGENETICS; DISEASE FREE SURVIVAL; GENETICS; HOSPITALIZATION; INCIDENCE; METABOLISM; MORTALITY; PATHOLOGY; PHILADELPHIA 1 CHROMOSOME; PROBABILITY; SENSITIVITY AND SPECIFICITY; SURVIVAL; TIME;

CAUSE OF DEATH; COHORT STUDIES; CYTOGENETICS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; HUMANS; INCIDENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASM, RESIDUAL; PHILADELPHIA CHROMOSOME; PIPERAZINES; POLYMERASE CHAIN REACTION; PROBABILITY; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 68949108481     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.6999     Document Type: Article

References (24)

1. O'Brien SG, Guilhot F, Larson RA, et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004, 2003
2. Druker BJ, Guilhot F, O'Brien SG, et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417, 2006
3. Kantarjian H, Talpaz M, O'Brien S, et al: Survival benefit with imatinib mesylate versus interferon-α-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 108:1835-1840, 2006
4. Kantarjian H, Cortes J, O'Brien S, et al: Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: High incidence of early complete and major cytogenetic responses. Blood 101: 97-100, 2003
5. Kantarjian HM, Talpaz M, Cortes J, et al: Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571: Gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res 9:160-166, 2003
6. Hughes TP, Kaeda J, Branford S, et al: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423-1432, 2003
7. Branford S, Seymour J, Grigg A, et al: BCRABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 13:7080-7086, 2007
8. Kantarjian H, O'Brien S, Shan J, et al: Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia - need for new response definitions? Cancer 112:837-845, 2008
9. Press R, Galderisi C, Yang R, et al: A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res 13:6136-6144, 2007
10. Branford S, Rudzki Z, Parkinson I, et al: Realtime quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 104:2926-2932, 2004
11. Wang L, Knight K, Lucas C, et al: The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. Haematologica 91:235-239, 2006
12. Hughes TP, Deininger MW, Hochhaus A, et al: Monitoring CML patients responding to treatment with tyrosine kinase inhibitors - review and recommendations for "harmonizing" current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108:28-37, 2006
13. Kantarjian H, Talpaz M, O'Brien S, et al: Highdose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103:2873-2878, 2004
14. Cortes J, Giles F, O'Brien S, et al: Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-α. Blood 102:83-86, 2003
15. Talpaz M, Shah NP, Kantarjian H, et al: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354:2531-2541, 2006
16. Kantarjian H, Giles F, Wunderle L, et al: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354:2542-2551, 2006
17. Bruemmendorf T, Cervantes F, Kim D, et al: Bosutinib is safe and active in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. J Clin Oncol 26:372s, 2008 (suppl; abstr 7001)
18. Press R, Love Z, Tronnes A, et al: BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood 107:4250-4256, 2006
19. Cortes J, Talpaz M, O'Brien S, et al: Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 11:3425-3432, 2005
20. Baccarani M, Saglio G, Goldman J, et al: Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108:1809-1820, 2006
21. Kantarjian H, Schiffer C, Jones D, et al: Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: Practical advice on the use and interpretation of monitoring methods. Blood 111: 1774-1780, 2008
22. Michallet M, Maloisel F, Chaleteix C, et al: Management of chronic myeloid leukemia in clinical practice in France; results of the French cohort of the unmet needs in CML (UNIC) study. Haematologica 93, 2008 (abstr 0545)
23. Steegmann JL, Michallet M, Morra E, et al: Use of imatinib in chronic phase CML in clinical practice: The UNIC study. Haematologica 93, 2008 (abstr 0126)
24. Abraham I, Noens L, De Bock R, et al: Non-adherence with imatinib treatment in chronic myeloid leukemia is a function of disease, health knowledge, and social factors - results from the Adagio study. Haematologica 93, 2008 (abstr 0551)